Cytokinetics (CYTK) : Bvf Incil scooped up 7,853 additional shares in Cytokinetics during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 4,997,071 shares of Cytokinetics which is valued at $55,967,195.Cytokinetics makes up approximately 9.21% of Bvf Incil’s portfolio.
Other Hedge Funds, Including , Parametric Portfolio Associates reduced its stake in CYTK by selling 996 shares or 7.02% in the most recent quarter. The Hedge Fund company now holds 13,200 shares of CYTK which is valued at $148,500.Geode Capital Management boosted its stake in CYTK in the latest quarter, The investment management firm added 1,817 additional shares and now holds a total of 273,668 shares of Cytokinetics which is valued at $2,846,147.Blackrock Fund Advisors boosted its stake in CYTK in the latest quarter, The investment management firm added 52,043 additional shares and now holds a total of 934,027 shares of Cytokinetics which is valued at $9,340,270. Strs Ohio sold out all of its stake in CYTK during the most recent quarter. The investment firm sold 64,900 shares of CYTK which is valued $632,126.
Cytokinetics (CYTK) witnessed a volatile trading activity on Monday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $11.2 and reached the intraday high at $11.55. The bulls started the profit booking and pushed the shares to intraday low of $10.95. The trading session was marked by a volume range of 2,36,956 shares exchanging hands. The 52-week high of the shares is $13.18 and the 52-week low is $6.0003. The market cap of the company stands at $450 M and there are 4,05,16,892 shares in public circulation.
Cytokinetics Incorporated is a clinical stage biopharmaceutical company. The Company is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. The Company’s drug candidates that are in clinical development are its skeletal muscle activators tirasemtiv and CK-2127107 and its cardiac muscle activator omecamtiv mecarbil. Tirasemtiv and CK-2127107 are structurally distinct and selective small molecules that activate the fast skeletal muscle troponin complex in the sarcomere by increasing its sensitivity to calcium leading to an increase in skeletal muscle contractility. COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure) is a Phase II clinical trial designed to assess the pharmacokinetics and tolerability of omecamtiv mecarbil dosed orally in patients with heart failure and left ventricular systolic dysfunction.